{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:09Z","timestamp":1793394969161,"version":"4.5.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.micpath.2025.108273","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:56:43Z","timestamp":1767113803000},"page":"108273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Gut microbiota's role in NAFLD- and HBV\/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications"],"prefix":"10.1016","volume":"211","author":[{"given":"Gursimran","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyam","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cancers15061687","article-title":"Causes of death among patients with hepatocellular carcinoma according to chronic liver disease etiology","volume":"15","author":"Yen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2018.07.022","article-title":"Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis","volume":"69","author":"Ganne-Carri\u00e9","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3350\/cmh.2023.0070","article-title":"The latest global burden of liver cancer: a past and present threat","volume":"29","author":"Oh","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J. Liver Cancer"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.micpath.2025.108273_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.944088","article-title":"The pathogenesis of HCC driven by NASH and the preventive and therapeutic effects of natural products","volume":"13","author":"Shao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41522-022-00352-6","article-title":"Host-microbiome interactions: gut-liver axis and its connection with other organs","volume":"8","author":"Anand","year":"2022","journal-title":"NPJ Biofilms Microb."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcmgh.2015.04.003","article-title":"The gut microbiota and liver disease","volume":"1","author":"Llorente","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","article-title":"Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib13","first-page":"209","article-title":"Microbial metabolites and immune modulation","volume":"3","author":"Ghasemi","year":"2024","journal-title":"J. Prevent. Compl. Med."},{"key":"10.1016\/j.micpath.2025.108273_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.775526","article-title":"The gut-liver axis in health and disease: the role of gut microbiota-derived signals in liver injury and regeneration","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.micpath.2025.108273_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911710","article-title":"Research progress on the therapeutic effect of polysaccharides on non-alcoholic fatty liver disease through the regulation of the gut\u2013liver axis","volume":"23","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.micpath.2025.108273_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158819","article-title":"TLR4 deficiency protects against hepatic fibrosis and diethylnitrosamine-induced pre-carcinogenic liver injury in fibrotic liver","volume":"11","author":"Weber","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.108273_bib17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70121","article-title":"The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions","volume":"6","author":"Yuan","year":"2025","journal-title":"MedComm"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib19","first-page":"377","article-title":"Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease","volume":"3","author":"Bieghs","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib20","first-page":"131","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention","volume":"1","author":"Baffy","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4251\/wjgo.v14.i5.947","article-title":"Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: current knowledge and potential for therapeutics","volume":"14","author":"Said","year":"2022","journal-title":"World J. Gastrointest. Oncol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib22","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/HEP.0000000000000406","article-title":"The role of the gut microbiome in the development of hepatobiliary cancers","volume":"80","author":"Daniel","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/medicina58060761","article-title":"An update on the chemokine system in the development of NAFLD","volume":"58","author":"Nagata","year":"2022","journal-title":"Medicina (B Aires)"},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/cells14020084","article-title":"Gut microbiome modulation in hepatocellular carcinoma: preventive role in NAFLD\/NASH progression and potential applications in immunotherapy-based strategies","volume":"14","author":"Monti","year":"2025","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.micpath.2025.108273_bib28","doi-asserted-by":"crossref","first-page":"8164","DOI":"10.3390\/ijms23158164","article-title":"Hepatocellular carcinoma: understanding the inflammatory implications of the microbiome","volume":"23","author":"Khalyfa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2025.108273_bib29","article-title":"The role of gut microbiota in some liver diseases: from an immunological perspective","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.micpath.2025.108273_bib30","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.3390\/cancers13205045","article-title":"Inflammatory and non-inflammatory mechanisms controlling cirrhosis development","volume":"13","author":"S\u00e1nchez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.micpath.2025.108273_bib31","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/cancers15102795","article-title":"The role of TLR4 in the immunotherapy of hepatocellular carcinoma: can we teach an old dog new tricks?","volume":"15","author":"Papadakos","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3350\/cmh.2022.0039","article-title":"Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4","volume":"28","author":"Liu","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41418-019-0340-7","article-title":"Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.micpath.2025.108273_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2022.111259","article-title":"Lactobacillus plantarum ZY08 relieves chronic alcohol-induced hepatic steatosis and liver injury in mice via restoring intestinal flora homeostasis","volume":"157","author":"Ding","year":"2022","journal-title":"Food Res. Int."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.micpath.2025.108273_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00394-017-1524-x","article-title":"Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis","volume":"57","author":"de Faria Ghetti","year":"2018","journal-title":"Eur. J. Nutr."},{"issue":"11","key":"10.1016\/j.micpath.2025.108273_bib38","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.3390\/molecules27113401","article-title":"The role of bile acids in the human body and in the development of diseases","volume":"27","author":"Shulpekova","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2025.108273_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1514872","article-title":"Carcinogenic and anticancer activities of microbiota-derived secondary bile acids","volume":"15","author":"Kouhzad","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.micpath.2025.108273_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2025.05.015","article-title":"The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity","author":"He","year":"2025","journal-title":"J. Adv. Res."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/biomedicines10030524","article-title":"The role of gut\u2013liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC","volume":"10","author":"Song","year":"2022","journal-title":"Biomedicines"},{"issue":"23","key":"10.1016\/j.micpath.2025.108273_bib42","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.3390\/nu14234950","article-title":"Recent advances in the digestive, metabolic and therapeutic effects of farnesoid X receptor and fibroblast growth factor 19: from cholesterol to bile acid signaling","volume":"14","author":"Di Ciaula","year":"2022","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.micpath.2025.108273_bib43","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/pharmaceutics15102460","article-title":"Interplay of extracellular vesicles and TLR4 signaling in hepatocellular carcinoma pathophysiology and therapeutics","volume":"15","author":"Papadakos","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2025.108273_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.873160","article-title":"Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Microbiol."},{"issue":"11","key":"10.1016\/j.micpath.2025.108273_bib45","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jgh.15027","article-title":"Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non\u2010alcoholic fatty liver disease","volume":"35","author":"Chen","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib46","article-title":"Bile acid metabolism in health and ageing-related diseases","author":"Li","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib47","first-page":"144","article-title":"Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma","volume":"21","author":"Song","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.micpath.2025.108273_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-319-95828-6_5","article-title":"Etiopathogenesis of NAFLD: Diet, gut, and NASH","author":"Miele","year":"2020","journal-title":"Non-Alcoholic Fatty Liver Disease: A 360-degree Overview"},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib55","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/cancers12030641","article-title":"Inflammatory mechanisms of HCC development","volume":"12","author":"Refolo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.micpath.2025.108273_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fcell.2020.00139","article-title":"Involvement of nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome in the pathogenesis of liver diseases","volume":"8","author":"Shi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22022-5","article-title":"Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease","volume":"12","author":"El Aggan","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.108273_bib60","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3389\/fimmu.2017.01728","article-title":"Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib51","first-page":"1","article-title":"Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs)","volume":"66","author":"Ratajczak","year":"2019","journal-title":"Acta Biochim. Pol."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101843","article-title":"Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: a case-control and an intervention study","volume":"46","author":"Zhu","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.micpath.2025.108273_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115861","article-title":"NLRP3 inflammasome in hepatic diseases: a pharmacological target","volume":"217","author":"Ramos-Tovar","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib63","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.30252","article-title":"NLR family pyrin domain\u2010containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice","volume":"69","author":"Inzaugarat","year":"2019","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.micpath.2025.108273_bib64","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.3390\/ijms25084537","article-title":"NLRP3 inflammasome in acute and chronic liver diseases","volume":"25","author":"Sayaf","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib65","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/microorganisms13051053","article-title":"Gut microbiota and the gut\u2013liver axis in liver disease: from chronic viral hepatitis to cirrhosis, hepatocellular carcinoma, and microbiome-based therapies","volume":"13","author":"Laivacuma","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2025.108273_bib66","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fmicb.2019.01575","article-title":"Longitudinal survey of fungi in the human gut: ITS profiling, phenotyping, and colonization","volume":"10","author":"Raimondi","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.108273_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/9781119904786.ch5","article-title":"Dysbiosis and its varied impacts","author":"Sharma","year":"2023","journal-title":"Gut Microbiota Health Dis."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.dld.2023.06.017","article-title":"Impacts of gut microbiota alteration on age-related chronic liver diseases","volume":"56","author":"Adhikary","year":"2024","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib70","article-title":"Chronic hepatitis B virus persistence: mechanisms and insights","volume":"17","author":"Naidu","year":"2025","journal-title":"Cureus"},{"issue":"28","key":"10.1016\/j.micpath.2025.108273_bib71","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.3748\/wjg.v28.i28.3555","article-title":"Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: molecular mechanisms and therapeutic inventions","volume":"28","author":"Li","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.micpath.2025.108273_bib72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00248-011-9925-5","article-title":"Changes of fecal bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease","volume":"63","author":"Xu","year":"2012","journal-title":"Microb. Ecol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib73","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2155018","article-title":"Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response","volume":"15","author":"Shen","year":"2023","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.micpath.2025.108273_bib74","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1073\/pnas.1424775112","article-title":"Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota","volume":"112","author":"Chou","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib75","article-title":"Advances in gut microbiota of viral hepatitis cirrhosis","volume":"2019","author":"Wang","year":"2019","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13099-023-00549-w","article-title":"Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease","volume":"15","author":"Lin","year":"2023","journal-title":"Gut Pathog."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70395","article-title":"Reduction of Bacteroides fragilis in gut microbiome of chronic hepatitis B patients promotes liver injury","volume":"97","author":"You","year":"2025","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cid\/ciy205","article-title":"Gut dysbiosis associated with hepatitis C virus infection","volume":"67","author":"Inoue","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib79","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/biology11050757","article-title":"Cancer-associated microbiota: from mechanisms of disease causation to microbiota-centric anti-cancer approaches","volume":"11","author":"Dey","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.micpath.2025.108273_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1119875","article-title":"Alterations of the gut microbiota associated with the occurrence and progression of viral hepatitis","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib81","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.aohep.2018.10.003","article-title":"A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma","volume":"18","author":"Pinero","year":"2019","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1285556","article-title":"Immune modulation of gut microbiota and its metabolites in chronic hepatitis B","volume":"14","author":"Li","year":"2023","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.micpath.2025.108273_bib95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/pathogens13080702","article-title":"Interplay between bile acids and intestinal microbiota: regulatory mechanisms and therapeutic potential for infections","volume":"13","author":"Li","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2025.108273_bib96","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fphar.2018.00939","article-title":"Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients","volume":"9","author":"\u0160arenac","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib98","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000321452","article-title":"Bile acids promote HCV replication through the EGFR\/ERK pathway in replicon-harboring cells","volume":"54","author":"Patton","year":"2011","journal-title":"Intervirology"},{"key":"10.1016\/j.micpath.2025.108273_bib99","article-title":"Bile acid metabolism and signalling in liver disease","author":"Fuchs","year":"2024","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hep.23009","article-title":"Endotoxemia and gut barrier dysfunction in alcoholic liver disease","volume":"50","author":"Rao","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib101","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/microorganisms7050121","article-title":"Role of gut microbiota in hepatocarcinogenesis","volume":"7","author":"Gupta","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2025.108273_bib103","first-page":"1","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib104","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11739-024-03600-z","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Comment","volume":"19","author":"Ribatti","year":"2024","journal-title":"Intern. Emerg. Med."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/cmi.2015.104","article-title":"Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies","volume":"13","author":"Ju","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib106","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/ijms23052707","article-title":"PD-1\/PD-L1 immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease","volume":"23","author":"Lombardi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2025.108273_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fmed.2019.00015","article-title":"Observational study of PD-L1, TGF-\u03b2, and immune cell infiltrates in hepatocellular carcinoma","volume":"6","author":"Ihling","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.micpath.2025.108273_bib108","article-title":"An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.108273_bib109","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.2147\/JIR.S300989","article-title":"The immunomodulatory functions of butyrate","author":"Siddiqui","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.micpath.2025.108273_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.108273_bib111","article-title":"Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"12","key":"10.1016\/j.micpath.2025.108273_bib112","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MEG.0b013e32834a75dc","article-title":"Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt","volume":"23","author":"Trebicka","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib113","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/gut.2008.156307","article-title":"Toll-like receptors as targets in chronic liver diseases","volume":"58","author":"Mencin","year":"2009","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib114","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12876-025-03589-5","article-title":"Associations between changes in the gut microbiota and liver cirrhosis: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4254\/wjh.v7.i3.425","article-title":"Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia","volume":"7","author":"Fukui","year":"2015","journal-title":"World J. Hepatol."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib116","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep4.1331","article-title":"Role of the gut\u2013liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship","volume":"3","author":"Ohtani","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib117","doi-asserted-by":"crossref","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","article-title":"Hepatic TLR4 signaling in obese NAFLD","volume":"309","author":"Sharifnia","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib118","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non\u2010alcoholic fatty liver disease: conspirators or competitors?","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib119","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.micpath.2025.108273_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.908011","article-title":"The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib121","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jam.13158","article-title":"Gut microbiota\u2010associated bile acid deconjugation accelerates hepatic steatosis in ob\/ob mice","volume":"121","author":"Park","year":"2016","journal-title":"J. Appl. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib122","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/biomedicines11041166","article-title":"Pathogenesis of hepatocellular carcinoma: the interplay of apoptosis and autophagy","volume":"11","author":"Kouroumalis","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.micpath.2025.108273_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.livres.2024.05.004","article-title":"Hepatitis B virus as a risk factor for hepatocellular carcinoma: there is still much work to do","author":"Abdelhamed","year":"2024","journal-title":"Liver Res."},{"key":"10.1016\/j.micpath.2025.108273_bib124","article-title":"Integrated analysis reveals the gut microbial metabolite TMAO promotes inflammatory hepatocellular carcinoma by upregulating POSTN","volume":"10","author":"Wu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.31083\/j.fbl2905182","article-title":"Roles and mechanisms of choline metabolism in nonalcoholic fatty liver disease and cancers","volume":"29","author":"Chen","year":"2024","journal-title":"Front. Biosci. Landmark"},{"issue":"11","key":"10.1016\/j.micpath.2025.108273_bib126","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1017\/S0007114524000631","article-title":"Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease","volume":"131","author":"Ma","year":"2024","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.micpath.2025.108273_bib127","doi-asserted-by":"crossref","DOI":"10.37349\/emed.2025.1001339","article-title":"TMAO metaorganismal pathway and chronic inflammatory diseases","volume":"6","author":"Wang","year":"2025","journal-title":"Explor. Med."},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib128","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3748\/wjg.v22.i4.1497","article-title":"Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma","volume":"22","author":"Sukowati","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib129","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12885-015-1384-9","article-title":"HBx induced AFP receptor expressed to activate PI3K\/AKT signal to promote expression of Src in liver cells and hepatoma cells","volume":"15","author":"Zhu","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/cancers15020533","article-title":"Hepatitis virus and hepatocellular carcinoma: recent advances","volume":"15","author":"Shen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.37349\/etat.2024.00209","article-title":"The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates","volume":"5","author":"Agustiningsih","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"issue":"33","key":"10.1016\/j.micpath.2025.108273_bib132","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.3748\/wjg.v27.i33.5488","article-title":"Microbiota and viral hepatitis: state of the art of a complex matter","volume":"27","author":"Milosevic","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.micpath.2025.108273_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984728","article-title":"Molecular pathogenesis: connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.108273_bib134","series-title":"Seminars in Liver Disease","first-page":"26","article-title":"Inflammation and liver cancer: molecular mechanisms and therapeutic targets","author":"Yang","year":"2019"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib135","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in Non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.108273_bib136","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fendo.2019.00611","article-title":"Gut dysfunction and non-alcoholic fatty liver disease","volume":"10","author":"Grabherr","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib137","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/cells9010176","article-title":"Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis","volume":"9","author":"Quesada-V\u00e1zquez","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.micpath.2025.108273_bib138","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.micpath.2025.108273_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114586","article-title":"Microbiota-derived short-chain fatty acids and modulation of host-derived peptides formation: focused on host defense peptides","volume":"162","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10555-023-10117-y","article-title":"Short-chain fatty acids in cancer pathogenesis","volume":"42","author":"Feitelson","year":"2023","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib141","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5005\/jp-journals-10054-0208","article-title":"Comparative study of serum levels of gamma-glutamyl transferase, Aspartate aminotransferase (AST), Alanine Transaminase (ALT), AST: ALT, and bilirubin in patients with chronic hepatitis","volume":"26","author":"Jain","year":"2023","journal-title":"Indian J. Med. Biochem."},{"key":"10.1016\/j.micpath.2025.108273_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1104399","article-title":"Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis","volume":"12","author":"Shi","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2025.108273_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1155306","article-title":"Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials","volume":"10","author":"Cao","year":"2023","journal-title":"Front. Nutr."},{"issue":"11","key":"10.1016\/j.micpath.2025.108273_bib144","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3390\/nu11112642","article-title":"The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies","volume":"11","author":"Meroni","year":"2019","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib145","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2281017","article-title":"Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs\u2013is it a new perspective for personalized treatment of cancer patients?","volume":"15","author":"Ka\u017amierczak-Siedlecka","year":"2023","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.micpath.2025.108273_bib146","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","article-title":"Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome","volume":"11","author":"Lee","year":"2020","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib147","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib148","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s12029-024-01095-7","article-title":"Concomitant medications alter clinical outcomes in patients with advanced digestive tract cancer receiving PD-1 checkpoint inhibitors combined with antiangiogenetic agents","volume":"55","author":"Wang","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.micpath.2025.108273_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772532","article-title":"Adjunctive probiotic lactobacillus rhamnosus probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104952","article-title":"Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid","volume":"100","author":"Lau","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.micpath.2025.108273_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104952","article-title":"Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid","volume":"100","author":"Lau","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib153","article-title":"Prebiotics: a novel approach to treat hepatocellular carcinoma","volume":"2017","author":"Fatima","year":"2017","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib154","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4254\/wjh.v14.i2.372","article-title":"Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma","volume":"14","author":"Russo","year":"2022","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib155","doi-asserted-by":"crossref","DOI":"10.2174\/0118715206364200250304034753","article-title":"Gut microbiota and the gut-liver axis in hepatocellular carcinoma: a comprehensive review of pathogenesis and therapeutic strategies","author":"Yadav","year":"2025","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib156","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/microorganisms8020175","article-title":"Biostimulating gut microbiome with bilberry anthocyanin combo to enhance anti-PD-L1 efficiency against murine colon cancer","volume":"8","author":"Liu","year":"2020","journal-title":"Microorganisms"},{"issue":"8","key":"10.1016\/j.micpath.2025.108273_bib157","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Activity of cecropin P1 and FA-LL-37 against urogenital microflora","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib158","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00171.2024","article-title":"Fecal microbiome transfer an investigative tool and treatment strategy in cancer","author":"Bohm","year":"2024","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib159","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/ajco.14139","article-title":"Impact of antibiotics and chronic medications on efficacy of immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"21","author":"Ng","year":"2025","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib160","article-title":"Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma","volume":"5","author":"Pinato","year":"2023","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib161","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000518090","article-title":"Use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in hepatocellular carcinoma","volume":"10","author":"Cheung","year":"2021","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib162","first-page":"85","article-title":"Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta\u2010analysis","volume":"26","author":"Wang","year":"2012","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"issue":"7456","key":"10.1016\/j.micpath.2025.108273_bib163","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.108273_bib164","article-title":"The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib165","article-title":"Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma","volume":"5","author":"Pinato","year":"2023","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib166","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000518090","article-title":"Use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in hepatocellular carcinoma","volume":"10","author":"Cheung","year":"2021","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.micpath.2025.108273_bib167","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","article-title":"The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics","volume":"18","author":"Salminen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.micpath.2025.108273_bib168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.copbio.2013.10.006","article-title":"Rational identification of diet-derived postbiotics for improving intestinal microbiota function","volume":"26","author":"Klemashevich","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.micpath.2025.108273_bib169","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1182547","article-title":"Postbiotics in oncology: science or science fiction?","volume":"14","author":"Kudra","year":"2023","journal-title":"Front. Microbiol."},{"issue":"15","key":"10.1016\/j.micpath.2025.108273_bib170","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/nu16152400","article-title":"Postbiotics as adjuvant therapy in cancer care","volume":"16","author":"Balendra","year":"2024","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib171","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/cells14020084","article-title":"Gut microbiome modulation in hepatocellular carcinoma: preventive role in NAFLD\/NASH progression and potential applications in immunotherapy-based strategies","volume":"14","author":"Monti","year":"2025","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.micpath.2025.108273_bib172","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70914","article-title":"Gut microbiota and hepatocellular carcinoma: metabolic products and immunotherapy modulation","volume":"14","author":"Xiao","year":"2025","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.micpath.2025.108273_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2024.105372","article-title":"Factors underlying the long-term efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome","volume":"26","author":"El-Salhy","year":"2024","journal-title":"Microb. Infect."},{"key":"10.1016\/j.micpath.2025.108273_bib174","series-title":"Fecal Microbiota Transplantation Combined with anti-PD-1 Inhibitor for Unresectable or Metastatic Solid Cancers Refractory to anti-PD-1 Inhibitor","author":"Park","year":"2023"},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000521358","article-title":"The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies","volume":"11","author":"Kang","year":"2022","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib176","doi-asserted-by":"crossref","first-page":"G711","DOI":"10.1152\/ajpgi.00171.2024","article-title":"Fecal microbial transplants as investigative tools in cancer","volume":"327","author":"Bohm","year":"2024","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"8","key":"10.1016\/j.micpath.2025.108273_bib177","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.micpath.2025.108273_bib179","first-page":"1","article-title":"Gut\u2013liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice","author":"Wang","year":"2025","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib180","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2476561","article-title":"Dysregulation of gut microbiota stimulates NETs-driven HCC intrahepatic metastasis: therapeutic implications of healthy faecal microbiota transplantation","volume":"17","author":"Deng","year":"2025","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib181","doi-asserted-by":"crossref","first-page":"424","DOI":"10.21037\/hbsn.2017.08.04","article-title":"Improve gut microbiome: a new horizon of cancer therapy","volume":"6","author":"Fukui","year":"2017","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.micpath.2025.108273_bib182","article-title":"JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.micpath.2025.108273_bib185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4254\/wjh.v9.i3.119","article-title":"Dietary factors can protect against liver cancer development","volume":"9","author":"Koumbi","year":"2017","journal-title":"World J. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108273_bib186","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2240031","article-title":"Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions","volume":"15","author":"Rajapakse","year":"2023","journal-title":"Gut Microbes"},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib187","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00983-22","article-title":"The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma","volume":"10","author":"Huang","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib188","doi-asserted-by":"crossref","first-page":"901","DOI":"10.21037\/hbsn-24-517","article-title":"Novel biomarkers for hepatocellular carcinoma detection and treatment","volume":"13","author":"Yi","year":"2024","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"6","key":"10.1016\/j.micpath.2025.108273_bib189","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41416-024-02582-1","article-title":"Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma","volume":"130","author":"Cho","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib190","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2226922","article-title":"Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies","volume":"15","author":"Koning","year":"2023","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib191","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","article-title":"Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease","volume":"33","author":"Sharpton","year":"2021","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.micpath.2025.108273_bib192","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.3390\/ijms24054855","article-title":"Fecal metagenomics and metabolomics identifying microbial signatures in non-alcoholic fatty liver disease","volume":"24","author":"Pekkala","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib193","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"issue":"9","key":"10.1016\/j.micpath.2025.108273_bib194","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: a scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int. J. Publ. Health"},{"key":"10.1016\/j.micpath.2025.108273_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.918493","article-title":"Cost-effectiveness of pharmacogenomics-guided prescribing to prevent gene-drug-related deaths: a decision-analytic model","volume":"13","author":"van der Wouden","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib196","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12967-023-03940-y","article-title":"Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.micpath.2025.108273_bib197","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.02.010","article-title":"Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption","volume":"94","author":"Chu","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.micpath.2025.108273_bib198","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12967-023-03940-y","article-title":"Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025009982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025009982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:28:03Z","timestamp":1767875283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025009982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":179,"alternative-id":["S0882401025009982"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108273","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota's role in NAFLD- and HBV\/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108273"}}